AstraZeneca grants specified rights to Nexium and Vimovo to Grünenthal.
AstraZeneca has agreed to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal. The medicines are outside AstraZeneca’s three main therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory.
Nexium has lost compound patent protection in the majority of global markets. Vimovo is patent protected in most European markets until 2025. AstraZeneca will continue to commercialise Nexium in all markets outside Europe, where the Company retains the rights. On completion of the agreements, AstraZeneca will not retain any ownership rights to Vimovo globally, or to Nexium in Europe. Nexium sales in Europe in H1 2018 were $121million; Vimovo global sales excluding the US and Japan in the same period were $37million. AstraZeneca will continue to manufacture and supply Nexium under a long-term supply agreement/
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins